Fundraising FoxHercules Capital, Inc. — 2026 Investments
2 investments dated 2026 · listed companies and verified rows first · show all
Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform.
BiotechMedical DevicesWaltham, US
Romesh Subramanian, Ph.D.(Executive Officer)Richard Scalzo(Executive Officer)Joshua Brumm(Executive Officer, Director)Jonathan McNeill, M.D.(Executive Officer)inOxana Beskrovnaya, Ph.D.(Executive Officer)John G. Cox(President and Chief Executive Officer)in
Co-investorsAtlas VentureMPM BioImpactVida VenturesWellington ManagementForbionRA Capital
Intercom is a customer communication platform that serves businesses through a partner network of agencies, resellers, and technology integrators offering referral commissions and AI-powered implementation services.
AI & Machine LearningEnterprise SoftwareSaaSDublin, IE
Eoghan McCabe(Founder)Des Traynor(Founder)inCiaran Lee(Founder)David Barrett(Founder)Andrew G. Vajna(Founder)
Co-investors1435 Capital3Spoke Capital500 GlobalBessemer Venture PartnersChemistryCraft Ventures+14 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.